Relief Therapeutics Holding (XSWX:RLF) Scaled Net Operating Assets: 0.41 (As of Jun. 2025)


XSWX:RLF Relief Therapeutics Holding SA XSWX:RLF
20 GF Score
Price CHF3.00
GF Value CHF6.28
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding Scaled Net Operating Assets?

Relief Therapeutics Holding XSWX:RLF +4.90% 20 Scaled Net Operating Assets is 0.41 as of Jun. 2025. GuruFocus rates XSWX:RLF with a GF Score™ of 20/100 and a GF Value™ of CHF6.28. The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Relief Therapeutics Holding's operating assets for the quarter that ended in Jun. 2025 was CHF35.49 Mil. Relief Therapeutics Holding's operating liabilities for the quarter that ended in Jun. 2025 was CHF13.45 Mil. Relief Therapeutics Holding's Total Assets for the quarter that ended in Dec. 2024 was CHF53.22 Mil. Therefore, Relief Therapeutics Holding's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2025 was 0.41.


Relief Therapeutics Holding Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Scaled Net Operating Assets Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 1.79 0.51 0.22 0.31

Relief Therapeutics Holding Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.32 0.54 0.34 0.41

XSWX:RLF vs KTTA, OSRH, LIMN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Scaled Net Operating Assets falls into.


XSWX:RLF
20GF Score
Relief Therapeutics Holding SA XSWX:RLF
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relief Therapeutics Holding Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Relief Therapeutics Holding's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(38.144-14.417)/76.39
=0.31

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=53.224 - 15.08
=38.144

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16.56 - 1.663 - 0.48
=14.417

Relief Therapeutics Holding's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2025 )
=(Operating Assets (Q: Jun. 2025 )-Operating Liabilities (Q: Jun. 2025 ))/Total Assets (Q: Dec. 2024 )
=(35.487-13.454)/53.224
=0.41

where

Operating Assets(Q: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=47.987 - 12.5
=35.487

Operating Liabilities(Q: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=15.354 - 1.531 - 0.369
=13.454

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.41 mean?
Relief Therapeutics Holding (XSWX:RLF) has a Scaled Net Operating Assets of 0.41 as of Jun. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Scaled Net Operating Assets too high?
Relief Therapeutics Holding's current Scaled Net Operating Assets is 0.41. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Scaled Net Operating Assets compare to KTTA and OSRH?
Relief Therapeutics Holding's Scaled Net Operating Assets of 0.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Scaled Net Operating Assets is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Scaled Net Operating Assets of 0.41. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Scaled Net Operating Assets is 0.41. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Scaled Net Operating Assets is 0.41 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.

Key valuation signals for XSWX:RLF:

  • Scaled Net Operating Assets: 0.41
  • GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score

Get the complete analysis for XSWX:RLF

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.00
Price
CHF6.28
GF Value